Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus Cisplatin in Advanced Cutaneous Squamous Cell Carcinoma
NCT05490485Phase 2Unknown
- Sponsor
- Henan Cancer Hospital
- Start
- Aug 2022
- Primary completion
- Jul 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in cutaneous squamous cell carcinoma (cSCC), sponsored by Henan Cancer Hospital. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT05490485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05490485.